---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-073322"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:24:46.716858+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Invivyd announces VYD222 shows neutralizing activity against KP.1.1 and KP.3 SARS-CoV-2 variants

## Summary
- VYD222 demonstrated in vitro neutralization of KP.1.1 FLiRT and KP.3 variants in pseudovirus assays.
- Epitope at VYD222 binding interface is 99.8% conserved among 2024 GISAID sequences.
- Next candidate VYD2311 also shows continued in vitro neutralization against these dominant strains.
- FLiRT variants account for >50% of circulating SARS-CoV-2 sequences as of June 8, 2024.
- CDC predicts KP.3 will become the most dominant lineage nationally in the near term.

## SEC filing metadata
- accession: 0000950170-24-073322
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017024073322/0000950170-24-073322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017024073322/ivvd-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-073322
- JSON: https://secwatch.observer/filing/0000950170-24-073322.json
- Plain text: https://secwatch.observer/filing/0000950170-24-073322.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.